Pharmaceutical laboratories face new drug reference price updates for 2026

The Ministry of Health has issued Order SND/1053/2026, of October 1, which proceeds with the 2026 update of the drug reference price system within the Spanish National Health System (SNS). This annual regulatory mechanism is designed to manage pharmaceutical spending and ensure the long-term sustainability of the public healthcare system by establishing standardized pricing for groups of similar medicinal products.

What changes

The primary objective of Order SND/1053/2026 is the annual modification of the reference price sets. According to the provisions of the Order and in accordance with Article 5.1 of Royal Decree 177/2014, the Ministry performs three specific actions: the establishment of new reference sets, the revision of prices for existing sets, and the removal of sets that no longer meet the legal requirements for their maintenance. These sets are organized according to the fifth level of the Anatomical Therapeutic Chemical (ATC5) classification of the World Health Organization (WHO) and must share an identical route of administration.

A significant technical detail in this update is the decision regarding essential medicines. To guarantee the continuous supply of critical treatments, the Ministry has opted not to revise the reference prices for certain presentations classified as 'essential' by the WHO. This measure is legally grounded in the explanatory part of Royal Decree 177/2014, which allows for exceptional corrective measures to preserve the general interest and ensure the availability of highly efficient medicines. Furthermore, Annex 8 of the Order lists medicinal presentations that have been exempted from the reference price system by the Interministerial Commission on Drug Prices.

Context

The reference price system is a fundamental pillar of pharmaceutical financing in Spain. It is regulated primarily by Article 98 of the consolidated text of the Law on Guarantees and Rational Use of Medicines and Medical Products, approved by Royal Legislative Decree 1/2015. This legal framework empowers the Ministry of Health to implement annual updates to control the economic impact of drug dispensing within the SNS.

This specific Order (BOE-A-2026-20825) directly updates the previous regulatory framework established by Order SND/1118/2025, of October 6, which governed the 2025 pricing cycle. The current update follows the procedural requirements set out in Royal Decree 177/2014 and the recent modifications introduced by Law 11/2020 to the consolidated text of the Medicines Law. By updating these prices annually, the administration ensures that the financing of the National Health System remains aligned with current market realities and therapeutic advancements.

Who is affected and how

Pharmaceutical laboratories and manufacturers: This group faces the most direct impact. The update necessitates a thorough assessment of profit margins and industrial prices. Since the reference price determines the maximum amount the National Health System will finance for a group of drugs, manufacturers of products included in newly established or revised sets must align their commercial strategies with these new ceilings to remain competitive and ensure reimbursement.

Pharmacies and distributors: The adjustment of reference prices affects the cost of financing and the dispensing processes. Pharmacies must adapt their inventory and billing systems to reflect the new prices and sets approved for the 2026 period to ensure correct reimbursement from the public system.

Patients and users of the National Health System: While the regulation is a macro-economic tool, it directly affects the end consumer. The reference price system influences which medicinal presentations are more accessible or more affordable for patients under public financing. The protection of 'essential medicines' ensures that patients relying on critical treatments do not face supply disruptions due to price volatility.

An example

Based on the data provided in Annex 1 of the Order, we can observe how specific products are categorized. For instance, in the ATC5 group 13C-urea (Oral route), the presentation 'UBTEST 100 mg film-coated tablets' is assigned a reference price (PVL) of 19.51 EUR and a retail price (PVP) of 30.46 EUR. If a manufacturer's industrial price exceeds the limits established by these reference sets, they may find it difficult to participate in the public financing scheme for that specific group of medications.

What to do and when

This Order is an administrative act that concludes the administrative route. Therefore, if any affected entity disagrees with the updated prices or the composition of the sets, they must adhere to the following legal deadlines:

• Administrative Appeal for Reversal (Recurso de Reposición): Affected parties may file an optional appeal before the Minister of Health within one month of the publication of the Order, pursuant to Articles 123 and 124 of Law 39/2015.
• Contentious-Administrative Appeal (Recurso Contencioso-Administrativo): If the party wishes to pursue judicial review, they must file an appeal before the Contentious-Administrative Chamber of the National Court (Audiencia Nacional) within two months of the day following the publication of the Order, in accordance with Article 11 of Law 29/1998.

We recommend that pharmaceutical companies conduct a technical audit of their product portfolios against the new Annexes to identify immediate impacts on their commercial operations. For specific legal guidance regarding the filing of appeals or the impact on your specific product line, please consult with the relevant specialist area at BMC.